Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Vertex Pharmaceuticals Inc
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Prev close 514.50 · gapped above the open, then crossed back over prior close. High/low 519.77 at 4:45 am ET, 512.19 at 10:15 am ET.
Each disclosed tie as a share of both companies’ annual revenue. The bigger share is the side that would feel it if the relationship ended.
| Partner | % of their revenue | % of VRTX revenue | Skew |
|---|---|---|---|
| SEPNSepterna, Inc. | 100.00% | 0.38% | 261× |
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“In addition, in December 2023, we and Vertex Pharmaceuticals Incorporated ("Vertex") entered into a license agreement (the "Vertex License Agreement"), under which Vertex obtained a non-exclusive license for our Cas9 gene editing technology for ex vivo gene editing medicines targeting the BCL11A gene in the fields of SCD and TDT, including Vertex's CASGEVY TM (exagamglogene autotemcel).”
FILING10-K0001650664-26-000017cik 0001650664disclosed by EDIT
“In August 2025, we received a $12.5 million milestone payment from Vertex Pharmaceuticals Incorporated ("Vertex") (see "Vertex Asset Purchase Agreement").”
FILING10-K0001193125-26-098507cik 0001984086disclosed by SEPN
“Substantially all of our revenue to date has been derived from the Vertex Agreement.”
FILING10-K0001689375-26-000011cik 0001689375disclosed by TRDA
“Pursuant to our agreement (the "CFF Agreement") with the Cystic Fibrosis Foundation (the "CFF"), our tiered third-party royalties on sales of ALYFTREK, TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, KALYDECO, and ORKAMBI, calculated as a percentage of net sales, range from the single digits to the sub-teens, with lower royalties on sales of ALYFTREK and TRIKAFTA/KAFTRIO than for our other products.”
FILING10-K0000875320-26-000056cik 0000875320
“Pursuant to the terms and conditions of the Vertex Agreement, Vertex has granted us an exclusive license under specified Vertex patent rights, including US patent No. 5,945,418, which relates to the composition of matter for neflamapimod.”
FILING10-K0001437749-26-008259cik 0001053691disclosed by CRVO
“Collaboration revenue was $35.0 million for the year ended December 31, 2024 and was related to Vertex's achievement of a $10.0 million research milestone and $25.0 million research milestone under the Non-Ex License Agreement with Vertex in 2024.”
FILING10-K0001193125-26-048957cik 0001674416disclosed by CRSP
“Zai licensed povetacicept for mainland China, Hong Kong SAR, Macau SAR, Taiwan region, and Singapore, while Ono licensed povetacicept for Japan and South Korea.”
FILING10-K0000875320-26-000056cik 0000875320
“Zai licensed povetacicept for mainland China, Hong Kong SAR, Macau SAR, Taiwan region, and Singapore, while Ono licensed povetacicept for Japan and South Korea.”
FILING10-K0000875320-26-000056cik 0000875320
“In July 2016, we entered into a Strategic Collaboration and License Agreement (Vertex Agreement) with Vertex Pharmaceuticals Incorporated, and Vertex Pharmaceuticals (Europe) Limited (together, Vertex).”
FILING10-K0001682852-26-000033cik 0001682852disclosed by MRNA
“An exclusive global license agreement with WuXi Biologics to develop and commercialize a trispecific T cell engager for B cell-mediated autoimmune diseases, which is currently in preclinical development.”
FILING10-K0000875320-26-000056cik 0000875320
Watchlist prices, news filtered to it, and its next report on your desk.
Vertex Pharmaceuticals Inc has 7 disclosed suppliers and 3 disclosed customers. Each one is named in an SEC filing, either Vertex Pharmaceuticals Inc’s own annual report or the counterparty’s, and carries the sentence that discloses it.
VRTX (Vertex Pharmaceuticals Inc) has 7 disclosed suppliers and 3 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: EDIT −4.20%, in healthcare.